Newron’s Dual Narrative: FDA Speed Bump Meets Analyst Caution as Schizophrenia Data Looms

The story at Newron SpA is one of mixed signals that would test any investor’s nerve. A regulatory pause on patient enrolment in a pivotal schizophrenia study triggered the usual concern, yet the stock has staged a surprising rally over the past two weeks. Adding to the dissonance, H.C. Wainwright recently trimmed its price target on the biotech firm while reaffirming a buy rating.

The FDA’s intervention stemmed from a sudden death in a study participant outside the United States. The investigating physician saw no link to Evenamide, the experimental glutamate modulator, and an independent safety committee reviewed the available data – giving the green light for both ENIGMA-TRS trials to continue as planned. The clinical holds only affect new patient intake at US sites; recruitment continues in Argentina and India. Over 400 patients are already enrolled in the global ENIGMA-TRS-1 study across 21 countries.

Despite the FDA scare, the market has largely shrugged off the risk. Trading volumes have picked up, and the shares recently changed hands at around 15.20 euros – a far cry from the 52-week high of 32.95 euros reached in January but up roughly 90 percent over the past twelve months. On May 21, however, the stock shed 4.7 percent on the SIX Swiss Exchange after H.C. Wainwright cut its price objective from 48 to 44 francs, falling to about 13.90 francs on the day.

Should investors sell immediately? Or is it worth buying Newron SpA?

That analyst adjustment reflects a broader caution. Since the start of 2025, the stock has lost more than 42 percent, and its annualised volatility hovers near 76 percent – a signature of a high-risk biotech play. Technically, the shares remain below the 200-day moving average at roughly 18 euros, a level that represents stiff resistance. A sustained breakout above that mark would confirm the recent uptrend as more than a dead-cat bounce.

Away from the clinical and market drama, Newron has refreshed its boardroom. At the annual general meeting on 20 April, shareholders approved all agenda items, including the election of two new independent non-executive directors. George Garibaldi, who brings over three decades of experience in CNS drug development, and Paolo Zocchi, a specialist in international capital markets, replace Patrick Langlois and Luca Benatti after long tenures.

The real inflection point for the company is the ENIGMA-TRS programme. Both studies – ENIGMA-TRS 1 and ENIGMA-TRS 2 – measure the change in the PANSS total score from baseline at 12 weeks, a standard yardstick for schizophrenia symptoms. Topline results from the first study are expected in the fourth quarter of 2026. Those data will determine whether Evenamide can truly help patients who do not respond to conventional antipsychotics.

For now, the FDA pause is a near-term cloud, but the underlying science remains the primary driver. The safety committee’s clear endorsement of continued enrolment should help alleviate regulatory concerns, though the company still needs to address the US agency’s requirements promptly. With the board now strengthened and a clear clinical roadmap ahead, Newron’s shares are in a waiting game until the next big catalyst – and the 2026 readout could either validate the current discount or prove a warning that the stock’s volatility was justified all along.

Ad

Newron SpA Stock: New Analysis - 23 May

Fresh Newron SpA information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Newron SpA analysis...

en | IT0004147952 | NEWRON’S | boerse | 69404481 |